Women's Health

Female vitiligo patients are at an increased risk of osteoporosis

Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…

Gynica to launch trial of cannabinoid-based endometriosis therapies

Israel-based Gynica will dose the first patient in a Phase I trial of its cannabinoid-based therapies IntraVagS301 and IntraVagS302 for…

AstraZeneca’s Imfinzi shows benefits in endometrial cancer trial

UK-based pharmaceutical company AstraZeneca has reported treatment benefits in findings from the DUO-E Phase III clinical trial of Imfinzi (durvalumab) plus Lynparza (olaparib).…

GSK’s Jemperli shows promise in endometrial cancer trial

GSK has announced promising results from the Phase III RUBY/ENGOT-EN6/GOG3031/NSGO clinical trial of the programmed death receptor-1 (PD-1)-hindering antibody Jemperli…

Affluent implants artificial sphincter in urinary incontinence study

French company Affluent Medical has completed the first successful implantation of its Artus device for the treatment of urinary incontinence.…

Opill marks first over-the-counter daily oral contraceptive in US

Manufacturer Perrigo announced on 4 March that Opill (norgestrel), the first daily over-the-counter birth control pill, will be available in…

Shifting patterns in cervical cancer cases in women in their 30s and 40s

Cervical cancer is one the most common cancers in women; its main cause is long-lasting infection with certain types of…

PhotonPharma receives FDA clearance for ovarian cancer vaccine trial

PhotonPharma has received clearance from the US Food and Drug Administration (FDA) to commence a Phase I clinical trial of…

Astellas doses first subject in Phase III menopausal VMS treatment trial

Astellas Pharma has dosed the first subject in the Phase III STARLIGHT 2 clinical trial of an oral, non-hormonal treatment…

UroMems champions positive results for stress urinary incontinence implant

UroMems has reported more positive results from a trial evaluating its UroActive device for the treatment of stress urinary incontinence.…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close